Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 12/20 | 0.51 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21410716 | 0.88 | FTO (0.42) | CAPN1TACR3POLBMAPTTDP1 | |
| SCHEMBL21854063 | 0.85 | CAPN1 (0.53) | CAPN1 | |
| SCHEMBL20028431 | 0.85 | CAPN1 (0.53) | CAPN1 | |
| SCHEMBL22886426 | 0.85 | FTO (0.42) | CAPN1POLBMAPTTDP1 | |
| SCHEMBL21411218 | 0.85 | CAPN1 (0.40) | CAPN1MAPT | |
| SCHEMBL22886561 | 0.83 | L3MBTL1 (0.42) | CAPN1TACR3POLBMAPTTDP1 | |
| SCHEMBL22886770 | 0.82 | PYGL (0.38) | CAPN1TACR3 | |
| SCHEMBL20027924 | 0.82 | CAPN1 (0.51) | CAPN1 | |
| SCHEMBL22886730 | 0.82 | L3MBTL1 (0.41) | CAPN1 | |
| SCHEMBL21854216 | 0.81 | CAPN1 (0.52) | CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021021816-A1 | CALPAIN INHIBITORS AND USES THEREOF FOR TREATING NEUROLOGICAL DISORDERS | BLADE THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | BLADE THERAPERTICS INC (US) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009564-A1 | CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF | CAPNS1, CAPN9, CAPN1 | CAPN1 3/4885TACR3 4071/4885POLB 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.